GLP 1

Exenatide is one of the cheaper branded GLP-1 drugs in 2026, partly because it is no longer top-of-class for either diabetes or weight loss.

Direct-to-consumer pharmaceutical advertising is legal in only two countries, the United States and New Zealand. Everywhere else it’s banned.

Endurance training and GLP-1 medications pull in opposite directions.

Most people who start semaglutide or tirzepatide come in thinking the drug will make them less hungry.

Compounded GLP-1 telehealth reviews need to be read carefully. The medications are powerful and the patient experience is individual.

LillyDirect Self-Pay is the direct-to-consumer cash channel Eli Lilly launched for Zepbound vials.

Efinopegdutide isn’t FDA-approved yet, so switching protocols are theoretical and based on standard GLP-1 class transitions.

Efinopegdutide is an investigational peptide drug.

Introduction Efinopegdutide’s side effect profile from phase 2 trials looks similar to other GLP-1-class weight loss drugs: dominant gastrointestinal complaints (nausea, vomiting, diarrhea, constipation),…